ATE403670T1 - Rückgefaltetes membranprotein in monodisperser form - Google Patents

Rückgefaltetes membranprotein in monodisperser form

Info

Publication number
ATE403670T1
ATE403670T1 AT04030315T AT04030315T ATE403670T1 AT E403670 T1 ATE403670 T1 AT E403670T1 AT 04030315 T AT04030315 T AT 04030315T AT 04030315 T AT04030315 T AT 04030315T AT E403670 T1 ATE403670 T1 AT E403670T1
Authority
AT
Austria
Prior art keywords
membrane protein
refolded
monodisperse form
monodisperse
preparing
Prior art date
Application number
AT04030315T
Other languages
English (en)
Inventor
Lars Linden
Stefan Prytulla
Thomas Ostermann
Monika Baehner
Tilmann Roos
Andreas Thess
Hans Kiefer
Wolfgang Vogt
Original Assignee
Phasys Gmbh M
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phasys Gmbh M filed Critical Phasys Gmbh M
Application granted granted Critical
Publication of ATE403670T1 publication Critical patent/ATE403670T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04030315T 2003-12-15 2003-12-15 Rückgefaltetes membranprotein in monodisperser form ATE403670T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/736,448 US20050130260A1 (en) 2003-12-15 2003-12-15 Refolded membrane protein in monodisperse form
EP03028803A EP1544209A1 (de) 2003-12-15 2003-12-15 Rückgefaltetes Membranprotein in monodisperser Form

Publications (1)

Publication Number Publication Date
ATE403670T1 true ATE403670T1 (de) 2008-08-15

Family

ID=34809734

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04030315T ATE403670T1 (de) 2003-12-15 2003-12-15 Rückgefaltetes membranprotein in monodisperser form

Country Status (6)

Country Link
US (1) US20050130260A1 (de)
EP (3) EP1544209A1 (de)
JP (1) JP2007537139A (de)
AT (1) ATE403670T1 (de)
DE (1) DE60322727D1 (de)
WO (1) WO2005058942A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
WO2007139471A2 (en) * 2006-05-31 2007-12-06 Ge Healthcare Bio-Sciences Ab Method for chromatography
US8226949B2 (en) * 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
JP5142267B2 (ja) * 2008-03-04 2013-02-13 独立行政法人産業技術総合研究所 短鎖両性界面活性剤
ES2586032T3 (es) 2008-03-28 2016-10-11 Hale Biopharma Ventures, Llc Administración de composiciones de benzodiazepinas
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
CN103796656A (zh) 2011-06-14 2014-05-14 哈尔生物药投资有限责任公司 苯二氮卓的投与
EP2957633A4 (de) 2013-02-15 2016-08-17 Nat Univ Corp Kyoto Inst Tech Verfahren zur rückfaltung eines antikörpers, verfahren zur herstellung eines rückgefalteten antikörpers, rückgefalteter antikörper und verwendungen davon
FR3020070B1 (fr) * 2014-04-22 2018-11-02 Universite Grenoble Alpes Proteines nadph oxydases
CN108753753B (zh) * 2018-05-28 2022-04-22 中国林业科学研究院林业研究所 Lrr受体激酶-pxy的纯化方法
CN110292916B (zh) * 2019-06-26 2020-11-03 中国科学院过程工程研究所 一种磷脂纳米盘层析介质及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9700566D0 (sv) * 1997-02-18 1997-02-18 Pharmacia & Upjohn Ab Modified proteins
AUPP380498A0 (en) * 1998-05-29 1998-06-25 Biomolecular Research Institute Limited Egf receptor agonists and antagonists
CA2376650C (en) * 1999-06-29 2008-01-15 University Health Network Peptide conjugates for the stabilization of membrane proteins and interactions with biological membranes
DE19939246A1 (de) * 1999-08-19 2001-02-22 Phasys Gmbh M Rückfaltung von Membranproteinen
WO2001073444A2 (en) * 2000-03-28 2001-10-04 Cambridge University Technical Services Limited Receptor/peptide crystal structure for identification of inhibitors
US7235367B2 (en) * 2000-07-12 2007-06-26 Genetics Institute, Llc. Method using crystal structure of estrogen receptor-β complex
WO2002043856A2 (en) * 2000-10-24 2002-06-06 Fatemeh Mojtabai Ordered two-and three-dimensional structures of amphiphilic molecules

Also Published As

Publication number Publication date
EP1550669A1 (de) 2005-07-06
EP1704163A1 (de) 2006-09-27
EP1544209A1 (de) 2005-06-22
WO2005058942A8 (en) 2006-08-03
US20050130260A1 (en) 2005-06-16
DE60322727D1 (de) 2008-09-18
WO2005058942A1 (en) 2005-06-30
JP2007537139A (ja) 2007-12-20
EP1550669B1 (de) 2008-08-06

Similar Documents

Publication Publication Date Title
DE60322727D1 (de) Rückgefaltetes Membranprotein in monodisperser Form
ATE446313T1 (de) Muteine von tränen-lipocalin
DK3085783T3 (da) Bispecifikt antistof som substitution for funktionelle proteiner
IL172512A0 (en) Fluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them
GB0327380D0 (en) Method
NO20050091L (no) Fremgangsmater for fremstilling av fibrinogen
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
WO2007075438A3 (en) Polypeptides comprising unnatural amino acids, methods for their production and uses therefor
EP1489188A4 (de) Reaktionslösung für zellfreie proteinsynthese, verfahren zur herstellung davon und proteinsyntheseverfahren unter verwendung davon
IL172729A0 (en) Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins
BRPI0507886A (pt) método de purificação de albumina compreendendo uma etapa de nanofiltração, solução e composição para uso terapêutico contendo-o
WO2004081033A3 (en) Synthesis of proteins by cell-free protein expression
DE60336822D1 (de) Verfahren zur herstellung von kristallinem 1,2-polybutadien
DE60210778D1 (de) Verfahren zur herstellung von 4-amino-2,5-bisheterocyclylchinazolinen
ATE413867T1 (de) Methode zur behandlung von bewegungsstörungen mit barbitursäure derivaten.
ATE374757T1 (de) Verfahren zur herstellung von (1,4,5)- oxadiazepinderivaten
NO20060535L (no) Aztreonam-L-lysin og fremgangsmater for fremstilling av dette
WO2005037191A3 (en) Expression of dominant negative transmembrane receptors in the milk of transgenic animals
WO2004020452A3 (en) Method for refolding neisserial nspa protein
AU2003268706A1 (en) PROCESS FOR PRODUCING OPTICALLY ACTIVE Alpha-SUBSTITUTED CYSTEINE OR SALT THEREOF, INTERMEDIATE THEREFOR, AND PROCESS FOR PRODUCING THE SAME
NO20064057L (no) Metode for a stimulere harvekst
FR2843277B1 (fr) Procede de culture de perles stimulee par des proteines d'origine nacriere
DE60205904D1 (de) Vorrichtung zur herstellung von legierungskristallen
EP1599578A4 (de) Verfahren zur verhinderung der gluconoylierung von proteinen
ATE397753T1 (de) Screening-verfahren für eine prophylaktische und therapeutische substanz für eine nierenerkrankung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties